ATE519779T1 - An das glu-pro motiv-bindende proteine und peptide, diese enthaltende therapeutische zusammensetzungen und deren anwendungen - Google Patents
An das glu-pro motiv-bindende proteine und peptide, diese enthaltende therapeutische zusammensetzungen und deren anwendungenInfo
- Publication number
- ATE519779T1 ATE519779T1 AT01402406T AT01402406T ATE519779T1 AT E519779 T1 ATE519779 T1 AT E519779T1 AT 01402406 T AT01402406 T AT 01402406T AT 01402406 T AT01402406 T AT 01402406T AT E519779 T1 ATE519779 T1 AT E519779T1
- Authority
- AT
- Austria
- Prior art keywords
- glu
- pro
- compositions containing
- motiv
- proteins
- Prior art date
Links
- YBTCBQBIJKGSJP-BQBZGAKWSA-N Glu-Pro Chemical compound OC(=O)CC[C@H](N)C(=O)N1CCC[C@H]1C(O)=O YBTCBQBIJKGSJP-BQBZGAKWSA-N 0.000 title abstract 3
- 239000000203 mixture Substances 0.000 title 1
- 102000004196 processed proteins & peptides Human genes 0.000 title 1
- 108090000765 processed proteins & peptides Proteins 0.000 title 1
- 102000004169 proteins and genes Human genes 0.000 title 1
- 108090000623 proteins and genes Proteins 0.000 title 1
- 230000001225 therapeutic effect Effects 0.000 title 1
- 235000001014 amino acid Nutrition 0.000 abstract 1
- 150000001413 amino acids Chemical class 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 229940079593 drug Drugs 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 238000012216 screening Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2799/00—Uses of viruses
- C12N2799/02—Uses of viruses as vector
- C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Zoology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Toxicology (AREA)
- General Chemical & Material Sciences (AREA)
- Gastroenterology & Hepatology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP01402406A EP1295895B1 (de) | 2001-09-19 | 2001-09-19 | An das Glu-Pro Motiv-bindende Proteine und Peptide, diese enthaltende therapeutische Zusammensetzungen und deren Anwendungen |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE519779T1 true ATE519779T1 (de) | 2011-08-15 |
Family
ID=8182881
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT01402406T ATE519779T1 (de) | 2001-09-19 | 2001-09-19 | An das glu-pro motiv-bindende proteine und peptide, diese enthaltende therapeutische zusammensetzungen und deren anwendungen |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20040171551A1 (de) |
| EP (2) | EP1295895B1 (de) |
| JP (1) | JP2005507249A (de) |
| AT (1) | ATE519779T1 (de) |
| AU (1) | AU2002343126A1 (de) |
| CA (1) | CA2460665A1 (de) |
| WO (1) | WO2003035682A2 (de) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2044949A1 (de) | 2007-10-05 | 2009-04-08 | Immutep | Verwendung von rekombinantem LAG-3 oder Derivaten daraus zur Auslösung einer Monozyten-Immunreaktion |
| AR072999A1 (es) | 2008-08-11 | 2010-10-06 | Medarex Inc | Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos |
| UY34887A (es) | 2012-07-02 | 2013-12-31 | Bristol Myers Squibb Company Una Corporacion Del Estado De Delaware | Optimización de anticuerpos que se fijan al gen de activación de linfocitos 3 (lag-3) y sus usos |
| SI3508502T1 (sl) | 2013-09-20 | 2023-07-31 | Bristol-Myers Squibb Company | Kombinacija anti-lag-3 protiteles in anti-pd-1 protiteles za zdravljenje tumorjev |
| GB201322626D0 (en) | 2013-12-19 | 2014-02-05 | Immutep S A | Combined preparations for the treatment of cancer |
| ES2716685T3 (es) | 2014-01-24 | 2019-06-14 | Dana Farber Cancer Inst Inc | Moléculas de anticuerpo para PD-1 y usos de las mismas |
| TWI777174B (zh) | 2014-03-14 | 2022-09-11 | 瑞士商諾華公司 | 針對lag-3之抗體分子及其用途 |
| GB201500374D0 (en) | 2015-01-09 | 2015-02-25 | Immutep S A | Combined preparations for the treatment of cancer |
| CN107921087A (zh) | 2015-07-16 | 2018-04-17 | 百欧肯治疗有限公司 | 治疗癌症的组合物及方法 |
| KR102713203B1 (ko) | 2017-05-30 | 2024-10-10 | 브리스톨-마이어스 스큅 컴퍼니 | Lag-3 양성 종양의 치료 |
| KR20240155979A (ko) | 2017-05-30 | 2024-10-29 | 브리스톨-마이어스 스큅 컴퍼니 | 항-lag-3 항체 또는 항-lag-3 항체 및 항-pd-1 또는 항-pd-l1 항체를 포함하는 조성물 |
| AU2021364837A1 (en) | 2020-10-23 | 2023-05-25 | Bristol-Myers Squibb Company | Lag-3 antagonist therapy for lung cancer |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE227586T1 (de) * | 1995-07-21 | 2002-11-15 | Applied Research Systems | Verfahren zur erkennung, identifizierung, isolierung, selektiver markierung und zielgerichteter erkennung von th1 lymphozyten mit hilfe von lag-3 protein |
| EP0900841A1 (de) * | 1997-06-18 | 1999-03-10 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Spleissvarianten von LAG-3 |
| EP0893507A1 (de) * | 1997-07-25 | 1999-01-27 | Institut Gustave Roussy | Verwendung von MHC Klass II Liganden (CD4 und LAG-3) als Adjuvanz für Impfungen und von LAG-3 in der Behandlung von Krebs |
| US5919616A (en) * | 1997-12-12 | 1999-07-06 | Aurx, Inc. | Serological assay for herpes |
-
2001
- 2001-09-19 AT AT01402406T patent/ATE519779T1/de not_active IP Right Cessation
- 2001-09-19 EP EP01402406A patent/EP1295895B1/de not_active Expired - Lifetime
-
2002
- 2002-09-17 WO PCT/IB2002/004240 patent/WO2003035682A2/en not_active Ceased
- 2002-09-17 CA CA002460665A patent/CA2460665A1/en not_active Abandoned
- 2002-09-17 AU AU2002343126A patent/AU2002343126A1/en not_active Abandoned
- 2002-09-17 JP JP2003538195A patent/JP2005507249A/ja active Pending
- 2002-09-17 EP EP02779791A patent/EP1427753A2/de not_active Withdrawn
-
2004
- 2004-03-18 US US10/803,366 patent/US20040171551A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| US20040171551A1 (en) | 2004-09-02 |
| JP2005507249A (ja) | 2005-03-17 |
| WO2003035682A3 (en) | 2003-09-25 |
| EP1427753A2 (de) | 2004-06-16 |
| EP1295895A1 (de) | 2003-03-26 |
| CA2460665A1 (en) | 2003-05-01 |
| EP1295895B1 (de) | 2011-08-10 |
| AU2002343126A1 (en) | 2003-05-06 |
| WO2003035682A2 (en) | 2003-05-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE519779T1 (de) | An das glu-pro motiv-bindende proteine und peptide, diese enthaltende therapeutische zusammensetzungen und deren anwendungen | |
| HUP0002454A2 (hu) | D-Vitamin-molekularésszel rendelkező konjugátumok és ilyen konjugátumokat tartalmazó gyógyászati készítmények | |
| BR0107613A (pt) | Bloqueio do crescimento de axÈnios mediado por receptor nogo | |
| NO984415D0 (no) | Peptider med antiproliferative egenskaper | |
| CY1117239T1 (el) | Συνδυαστικες συνθεσεις διπλοκοκκου του neisser | |
| BRPI0417341A (pt) | fator ix glicopeguilado | |
| ATE496063T1 (de) | Hybrid und tandemproteine von neisseria sp | |
| DK0409472T3 (da) | Knoglemorfogenetisk protein | |
| CA2181150A1 (en) | Biologically Active Peptides from Functional Domains of Bactericidal/Permeability-Increasing Protein and Uses Thereof | |
| RU95115239A (ru) | Аналог эритропоэтина | |
| EP2330127A3 (de) | Kalikrein-hemmende Kunitzdomänenproteine und Nukleinsäuren, die diese codieren | |
| NO20014508D0 (no) | Fremgangsmåte for acylering av peptider, og nye acyleringsmidler | |
| ATE169304T1 (de) | Biologisch aktive peptide aus funktionellen domaenen des bakteriziden/ die permeabilitaet erhoehenden proteins und ihre verwendung | |
| DE68916932D1 (de) | Antimikrobielle peptide, zusammensetzungen, die diese enthalten, und verwendungen daraus. | |
| ATE394484T1 (de) | Smad 6 und dessen anwendungen | |
| DE60020344D1 (de) | Cyanovirin konjugate, matrix-verankertes cyanovirin und anti-cyanovirin antikörper, und verwandte zusammensetzungen und anwendungen | |
| BR0312521A (pt) | Métodos para a separação e a purificação de fibrinogênio e de pelo menos uma outra proteìna e para a co-purificação de fibrinogênio e de fator xiii, uso de cromatografia de afinidade com ìon de metal imobilizado, fibrinogênio, kit farmacêutico, e, formulações farmacêutica e de fibrinogênio liofilizado | |
| DK1025236T3 (da) | Human checkpoint kinase, HCDS1, præparater og fremgangsmåde | |
| ATE331037T1 (de) | Isoliertes frpb nukleinsäuremolekül und entsprechende impfstoff | |
| DE68925275D1 (de) | Endotoxin-bindeprotein und dessen verwendung | |
| PT896615E (pt) | Peptido proveniente de uma forma soluvel de acetilcolinesterase activo como modulador dos canais de calcio | |
| DE69931482D1 (de) | Isolierte peptide die aminosäuresequenzen von ny-eso-1 entsprechen und an mhc-klasse i und mhc klasse ii moleküle binden, und deren verwendungen | |
| DK1079849T3 (da) | Anvendelse af HMG-proteiner til fremstilling af lægemidler med cytotoksisk virkning | |
| DE69700894D1 (de) | Kovalentgebundene Dimere von Glycopeptid-Antibiotika | |
| DE69309790D1 (de) | Cyclopentanperhydrophenanthren-17-beta-(3-Furyl)-3-Derivate und pharmazeutische Präparate davon, zur Behandlung von Kardiovaskulär-Erkrankungen |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |